Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
CANbridge Pharmaceuticals Inc. (HK:1228)
HKEX:1228
CANbridge Pharmaceuticals Inc. (1228) Stock Price & Analysis
0 Followers
1228 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$0.25 - HK$1.95
Previous CloseHK$0.33
Volume13.00K
Average Volume (3M)80.37K
Market Cap
HK$140.20M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Aug 21, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume80,371
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$12.30Price Target Upside3627.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
CANbridge Pharmaceuticals Inc. News
PremiumCompany Announcements
CANbridge Shareholders Approve All AGM Resolutions
PremiumCompany Announcements
CANbridge Pharmaceuticals Announces Key AGMOptions Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.83% Mutual Funds
0.00% Other Institutional Investors
99.17% Public Companies and
Individual Investors
1228 FAQ
What was CANbridge Pharmaceuticals Inc.’s price range in the past 12 months?
CANbridge Pharmaceuticals Inc. lowest stock price was HK$0.25 and its highest was HK$1.95 in the past 12 months.
What is CANbridge Pharmaceuticals Inc.’s market cap?
Currently, no data Available
When is CANbridge Pharmaceuticals Inc.’s upcoming earnings report date?
CANbridge Pharmaceuticals Inc.’s upcoming earnings report date is Aug 21, 2024 which is in 51 days.
How were CANbridge Pharmaceuticals Inc.’s earnings last quarter?
CANbridge Pharmaceuticals Inc. released its earnings results on Mar 28, 2024. The company reported -HK$0.409 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.409.
Is CANbridge Pharmaceuticals Inc. overvalued?
According to Wall Street analysts CANbridge Pharmaceuticals Inc.’s price is currently Undervalued.
Does CANbridge Pharmaceuticals Inc. pay dividends?
CANbridge Pharmaceuticals Inc. does not currently pay dividends.
What is CANbridge Pharmaceuticals Inc.’s EPS estimate?
CANbridge Pharmaceuticals Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CANbridge Pharmaceuticals Inc. have?
CANbridge Pharmaceuticals Inc. has 424,838,320 shares outstanding.
What happened to CANbridge Pharmaceuticals Inc.’s price movement after its last earnings report?
CANbridge Pharmaceuticals Inc. reported an EPS of -HK$0.409 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of CANbridge Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in HK:1228
---
CANbridge Pharmaceuticals Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.87%
12-Months-Change
Fundamentals
Return on Equity
-277.78%
Trailing 12-Months
Asset Growth
-44.77%
Trailing 12-Months
Company Description
CANbridge Pharmaceuticals Inc.
Canbridge Pharmaceuticals Inc is a global biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.
---
1228 Stock 12 Month Forecast
Average Price Target
HK$12.30
▲(3627.27% Upside)
Technical Analysis
Wuxi Sunlit Science & Technology Co., Ltd. Class H
―
GC Construction Holdings Limited
―
NVC International Holdings Ltd.
―
Best Analysts Covering 1228
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-43.80%
reiterated a buy rating 2 months ago
Copying Chris Lui's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -43.80% per trade.
---